Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 5/20 | 0.57 |
| ▸ | DRD3 | P35462 | 5/20 | 0.57 |
| ▸ | ANPEP | P15144 | 2/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL896147 | 1.00 | PLAU (1.00) | PLAUDRD2DRD3ANPEPOPRK1 | |
| SCHEMBL42952 | 1.00 | PLAU (1.00) | PLAUDRD2DRD3ANPEPOPRK1 | |
| SCHEMBL30368725 | 1.00 | PLAU (1.00) | PLAUDRD2DRD3ANPEPOPRK1 | |
| SCHEMBL29428767 | 1.00 | PLAU (1.00) | PLAUDRD2DRD3ANPEPOPRK1 | |
| SCHEMBL30038968 | 1.00 | PLAU (1.00) | PLAUDRD2DRD3ANPEPOPRK1 | |
| Hydrochloric Acid SCHEMBL756199 | 0.98 | PLAU (0.95) | PLAUDRD2DRD3ANPEPOPRK1 | |
| Charcoal, Activated SCHEMBL6230334 | 0.98 | PLAU (0.95) | PLAUDRD2DRD3ANPEPOPRK1 | |
| Ammonia Solution, Strong SCHEMBL20530707 | 0.98 | PLAU (0.95) | PLAUDRD2DRD3ANPEPOPRK1 | |
| Hydrochloric Acid SCHEMBL8991950 | 0.98 | PLAU (0.95) | PLAUDRD2DRD3ANPEPOPRK1 | |
| Benzene SCHEMBL299297 | 0.98 | PLAU (0.95) | PLAUDRD2DRD3ANPEPOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1568770-A2 | Pharmaceutical use of compounds which bind to a mammalian \"trace amine\" receptor | Oregon Health & Science University (US) | 2005-08-31 | — | — | EP | claimed |
| US-20040072187-A1 | Novel mammalian receptor genes and uses | OREGON HEALTH & SCIENCE UNIVERSITY | 2004-04-15 | — | — | US | claimed |
| EP-1319070-A2 | MAMMALIAN RECEPTOR GENES AND USES | Oregon Health & Science University (US) | 2003-06-18 | — | — | EP | claimed |
| WO-2002022801-A2 | MAMMALIAN RECEPTOR GENES AND USES | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2002-03-21 | — | — | WO | claimed |
| US-20240124412-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-04-18 | — | — | US | disclosed |
| CN-114075141-A | Opioid receptor 'bias' ligand, preparation method and application thereof in medicine | 上海致根医药科技有限公司 | 2022-02-22 | — | — | CN | disclosed |
| US-20200352931-A1 | OXALAMIDES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | Phenex Discovery Verwaltungs-GmbH (DE) | 2020-11-12 | — | — | US | disclosed |
| US-10646457-B2 | Emesis treatment | REPURPOSED THERAPEUTICS, INC (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190231714-A1 | EMESIS TREATMENT | REPURPOSED THERAPEUTICS, INC | 2019-08-01 | — | — | US | disclosed |
| WO-2019115586-A1 | OXALAMIDES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | Phenex Discovery Verwaltungs-GmbH (DE) | 2019-06-20 | — | — | WO | disclosed |
| US-10206889-B2 | Emesis treatment | REPURPOSED THERAPEUTICS, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180161287-A1 | EMESIS TREATMENT | EPIOMED THERAPEUTICS, INC. | 2018-06-14 | — | — | US | disclosed |
| US-20040072187-A1 | Novel mammalian receptor genes and uses | OREGON HEALTH & SCIENCE UNIVERSITY | 2004-04-15 | — | — | US | disclosed |
| EP-1319070-A2 | MAMMALIAN RECEPTOR GENES AND USES | Oregon Health & Science University (US) | 2003-06-18 | — | — | EP | disclosed |
| WO-2002022801-A2 | MAMMALIAN RECEPTOR GENES AND USES | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2002-03-21 | — | — | WO | disclosed |
| US-5300437-A | Using omega-amino acid transaminase | CELGENE CORPORATION (US) | 1994-04-05 | — | — | US | disclosed |
| US-5254595-A | Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them | ELF SANOFI (FR) | 1993-10-19 | — | — | US | disclosed |
| EP-0375560-B1 | ARYLOXYPROPANOLAMINOTETRALINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | ELF SANOFI (FR) | 1993-05-12 | — | — | EP | disclosed |
| EP-0375560-A1 | Aryloxypropanolaminotetralines, process for their preparation and pharmaceutical compositions containing same | ELF SANOFI (FR) | 1990-06-27 | — | — | EP | disclosed |
| US-3970650-A | DRUG INTERMEDIATE | A. CHRISTIAENS SOCIETE ANONYME (BE) | 1976-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200352931-A1 | OXALAMIDES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, INMT | PLAU 4090/4885DRD2 3426/4885DRD3 3296/4885 |
| US-10206889-B2 | Emesis treatment | SLC10A2, TTR, NTSR2 | PLAU 1758/4885DRD2 1468/4885DRD3 2308/4885 |
| US-10646457-B2 | Emesis treatment | SLC10A2, TTR, NTSR2 | PLAU 1758/4885DRD2 1468/4885DRD3 2308/4885 |
| US-20240124412-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | IKZF2, IKZF1, IKZF3 | PLAU 3936/4885DRD2 4825/4885DRD3 4818/4885 |
| US-20180161287-A1 | EMESIS TREATMENT | SLC10A2, TTR, NTSR2 | PLAU 1758/4885DRD2 1468/4885DRD3 2308/4885 |
| US-20190231714-A1 | EMESIS TREATMENT | SLC10A2, TTR, NTSR2 | PLAU 1758/4885DRD2 1468/4885DRD3 2308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.